Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2020

Open Access 01-12-2020 | Biomarkers | Research

Urinary expression of let-7c cluster as non-invasive tool to assess the risk of disease progression in patients with high grade non-muscle invasive bladder Cancer: a pilot study

Authors: Manuela Spagnuolo, Manuela Costantini, Mariaconsiglia Ferriero, Marco Varmi, Isabella Sperduti, Giulia Regazzo, Lucia Cicchillitti, Ana Belén Díaz Méndez, Giovanni Cigliana, Vincenzo Pompeo, Andrea Russo, Valentina Laquintana, Riccardo Mastroianni, Giulia Piaggio, Umberto Anceschi, Aldo Brassetti, Alfredo Bove, Gabriele Tuderti, Rocco Simone Flammia, Michele Gallucci, Giuseppe Simone, Maria Giulia Rizzo

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2020

Login to get access

Abstract

Background

High grade non-muscle-invasive bladder cancer (HG-NMIBC) is a heterogeneous disease with variable risk of progression. Urinary microRNAs are promising biomarkers for BC detection and surveillance. Let-7c-5p miRNA, clustered with miR-99a-5p and -125b-5p, is deregulated in cancer, including BC. The aim of this study is to evaluate urinary let-7c cluster expression in Ta/T1 HG-NMIBC patients and its impact on progression-free survival (PFS).

Methods

Quantitative Real-Time-Polymerase-Chain-Reaction (qRT-PCR) was used to analyze the let-7c cluster expression in 57 urine and 49 neoplastic paired tissue samples prospectively collected from transurethral resection (TUR) HG-NMIBC patients. Twenty urine and 10 bladder tissue samples were collected and analyzed as normal controls. QRT-PCR was also used to detect intra−/extra-cellular let-7c cluster in BC cells. Receiver Operating Characteristic (ROC) curves were used to identify urinary miRNAs cut-off values predicting T-stage and PFS. Uni/multivariable Cox regression was performed to identify predictors of PFS. A nomogram predicting progression risk and a decision curve analysis (DCA) were performed.

Results

Urinary let-7c was significantly up-regulated in patients compared with controls, while the whole cluster was down-regulated in tumor tissues. Supporting these findings, in vitro comparison of extra−/intra-cellular ratios of cluster levels between BC cells, showed a higher ratio for let-7c in HG-NMIBC versus low-grade cells. Urinary let-7c cluster expression was increased in higher T-stage and was an independent predictor of progression. Lower EORTC-score and downregulation of urinary cluster were predictors of higher PFS on univariable Cox regression, while on multivariable analysis only cluster expression was an independent progression predictor. On DCA, a benefit was evident for patients with a PFS probability > 20%.

Conclusions

Urinary let-7c cluster evaluation may improve prognosis, identifying patients at risk of progression and addressing early radical treatment.
Appendix
Available only for authorised users
Literature
1.
go back to reference Cambier S, Sylvester RJ, Collette L, Gontero P, Brausi MA, van Andel G, et al. EORTC Nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage ta-T1 Urothelial bladder Cancer patients treated with 1-3 years of maintenance Bacillus Calmette-Guérin. Eur Urol. 2016;69(1):60–9.CrossRef Cambier S, Sylvester RJ, Collette L, Gontero P, Brausi MA, van Andel G, et al. EORTC Nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage ta-T1 Urothelial bladder Cancer patients treated with 1-3 years of maintenance Bacillus Calmette-Guérin. Eur Urol. 2016;69(1):60–9.CrossRef
2.
go back to reference Siegel RL, Miller KD, Jemal A. Cancer statistics 2018. CA Cancer J Clin. 2018;68(1):7–30.CrossRef Siegel RL, Miller KD, Jemal A. Cancer statistics 2018. CA Cancer J Clin. 2018;68(1):7–30.CrossRef
3.
go back to reference Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, et al. EAU guidelines on non-muscle-invasive Urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71(3):447–61.CrossRef Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, et al. EAU guidelines on non-muscle-invasive Urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71(3):447–61.CrossRef
4.
go back to reference Peng Y, Croce CM. The role of MicroRNAs in human cancer. Signal Transduct Target Ther. 2016;1:15004.CrossRef Peng Y, Croce CM. The role of MicroRNAs in human cancer. Signal Transduct Target Ther. 2016;1:15004.CrossRef
5.
go back to reference Lodewijk I, Dueñas M, Rubio C, Munera-Maravilla E, Segovia C, Bernardini A, et al. Liquid biopsy biomarkers in bladder Cancer: a current need for patient diagnosis and monitoring. Int J Mol Sci. 2018;19(9):2514.CrossRef Lodewijk I, Dueñas M, Rubio C, Munera-Maravilla E, Segovia C, Bernardini A, et al. Liquid biopsy biomarkers in bladder Cancer: a current need for patient diagnosis and monitoring. Int J Mol Sci. 2018;19(9):2514.CrossRef
6.
go back to reference Larrea E, Sole C, Manterola L, Goicoechea I, Armesto M, Arestin M, et al. New Concepts in Cancer Biomarkers: Circulating miRNAs in Liquid Biopsies. Int J Mol Sci. 2016;17(5). Larrea E, Sole C, Manterola L, Goicoechea I, Armesto M, Arestin M, et al. New Concepts in Cancer Biomarkers: Circulating miRNAs in Liquid Biopsies. Int J Mol Sci. 2016;17(5).
7.
go back to reference Fendler A, Stephan C, Yousef GM, Kristiansen G, Jung K. The translational potential of microRNAs as biofluid markers of urological tumours. Nat Rev Urol. 2016;13(12):734–52.CrossRef Fendler A, Stephan C, Yousef GM, Kristiansen G, Jung K. The translational potential of microRNAs as biofluid markers of urological tumours. Nat Rev Urol. 2016;13(12):734–52.CrossRef
8.
go back to reference Yamada Y, Enokida H, Kojima S, Kawakami K, Chiyomaru T, Tatarano S, et al. MiR-96 and miR-183 detection in urine serve as potential tumour markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer Sci. 2011;102(3):522–9.CrossRef Yamada Y, Enokida H, Kojima S, Kawakami K, Chiyomaru T, Tatarano S, et al. MiR-96 and miR-183 detection in urine serve as potential tumour markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer Sci. 2011;102(3):522–9.CrossRef
9.
go back to reference Braicu C, Buiga R, Cojocneanu R, Buse M, Raduly L, Pop LA, et al. Connecting the dots between different networks: miRNAs associated with bladder cancer risk and progression. J Exp Clin Cancer Res. 2019;38:433.CrossRef Braicu C, Buiga R, Cojocneanu R, Buse M, Raduly L, Pop LA, et al. Connecting the dots between different networks: miRNAs associated with bladder cancer risk and progression. J Exp Clin Cancer Res. 2019;38:433.CrossRef
10.
go back to reference Yin XH, Jin YH, Cao Y, Wong Y, Weng H, Sun C, et al. Development of a 21-miRNA signature associated with the prognosis of patients with bladder cancer. Front Oncol. 2019;9:729.CrossRef Yin XH, Jin YH, Cao Y, Wong Y, Weng H, Sun C, et al. Development of a 21-miRNA signature associated with the prognosis of patients with bladder cancer. Front Oncol. 2019;9:729.CrossRef
11.
go back to reference Hofbauer SL, de Martino M, Lucca I, Haitel A, Susani M, Shariat SF, et al. A urinary microRNA (miR) signature for diagnosis of bladder cancer. Urol Oncol. 2018;36(12):531.e1–8.CrossRef Hofbauer SL, de Martino M, Lucca I, Haitel A, Susani M, Shariat SF, et al. A urinary microRNA (miR) signature for diagnosis of bladder cancer. Urol Oncol. 2018;36(12):531.e1–8.CrossRef
12.
go back to reference Pardini B, Cordero F, Naccarati A, Viberti C, Birolo G, Oderda M, et al. MicroRNA profiles in urine by next-generation sequencing can stratify bladder cancer subtypes. Oncotarget. 2018;9(29):20658–69.CrossRef Pardini B, Cordero F, Naccarati A, Viberti C, Birolo G, Oderda M, et al. MicroRNA profiles in urine by next-generation sequencing can stratify bladder cancer subtypes. Oncotarget. 2018;9(29):20658–69.CrossRef
13.
go back to reference Boyerinas B, Park SM, Hau A, Murmann AE, Peter ME. The role of let-7 in cell differentiation and cancer. Endocr Relat Cancer. 2010;17(1):F19–36.CrossRef Boyerinas B, Park SM, Hau A, Murmann AE, Peter ME. The role of let-7 in cell differentiation and cancer. Endocr Relat Cancer. 2010;17(1):F19–36.CrossRef
14.
go back to reference Tang H, Ma M, Dai J, Cui C, Si L, Sheng X, et al. miR-let-7b and miR-let-7c suppress tumourigenesis of human mucosal melanoma and enhance the sensitivity to chemotherapy. J Exp Clin Cancer Res. 2019;38:212.CrossRef Tang H, Ma M, Dai J, Cui C, Si L, Sheng X, et al. miR-let-7b and miR-let-7c suppress tumourigenesis of human mucosal melanoma and enhance the sensitivity to chemotherapy. J Exp Clin Cancer Res. 2019;38:212.CrossRef
15.
go back to reference Pelosi A, Careccia S, Sagrestani G, Nanni S, Manni I, Schinzari V, et al. Dual promoter usage as regulatory mechanism of let-7c expression in leukemic and solid tumours. Mol Cancer Res. 2014;12(6):878–89.CrossRef Pelosi A, Careccia S, Sagrestani G, Nanni S, Manni I, Schinzari V, et al. Dual promoter usage as regulatory mechanism of let-7c expression in leukemic and solid tumours. Mol Cancer Res. 2014;12(6):878–89.CrossRef
16.
go back to reference Nadiminty N, Tummala R, Lou W, Zhu Y, Shi XB, Zou JX, et al. MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth. PLoS One. 2012;7(3):e32832.CrossRef Nadiminty N, Tummala R, Lou W, Zhu Y, Shi XB, Zou JX, et al. MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth. PLoS One. 2012;7(3):e32832.CrossRef
17.
go back to reference Zhou H, Tang K, Xiao H, Zeng J, Guan W, Guo X, et al. A panel of eight-miRNA signature as a potential biomarker for predicting survival in bladder cancer. J Exp Clin Cancer Res. 2015;34:53.CrossRef Zhou H, Tang K, Xiao H, Zeng J, Guan W, Guo X, et al. A panel of eight-miRNA signature as a potential biomarker for predicting survival in bladder cancer. J Exp Clin Cancer Res. 2015;34:53.CrossRef
18.
go back to reference Vinall RL, Tepper CG, Ripoll AA, Gandour-Edwards RF, Durbin-Johnson BP, Yap SA, et al. Decreased expression of let-7c is associated with non-response of muscle-invasive bladder cancer patients to neoadjuvant chemotherapy. Genes Cancer. 2016;7(3–4):86–97.PubMedPubMedCentral Vinall RL, Tepper CG, Ripoll AA, Gandour-Edwards RF, Durbin-Johnson BP, Yap SA, et al. Decreased expression of let-7c is associated with non-response of muscle-invasive bladder cancer patients to neoadjuvant chemotherapy. Genes Cancer. 2016;7(3–4):86–97.PubMedPubMedCentral
19.
go back to reference Kamat AM, Flaig TW, Grossman HB, Konety B, Lamm D, O'Donnell MA, et al. Expert consensus document: consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. Nat Rev Urol. 2015;12(4):225–35.CrossRef Kamat AM, Flaig TW, Grossman HB, Konety B, Lamm D, O'Donnell MA, et al. Expert consensus document: consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. Nat Rev Urol. 2015;12(4):225–35.CrossRef
20.
go back to reference Bravo E, Calzolari A, De Castro P, Mabile L, Napolitani F, Rossi AM, et al. Developing a guideline to standardize the citation of bioresources in journal articles (CoBRA). BMC Med. 2015;13:33.CrossRef Bravo E, Calzolari A, De Castro P, Mabile L, Napolitani F, Rossi AM, et al. Developing a guideline to standardize the citation of bioresources in journal articles (CoBRA). BMC Med. 2015;13:33.CrossRef
21.
go back to reference Marchesi F, Regazzo G, Palombi F, Terrenato I, Sacconi A, Spagnuolo M, et al. Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study. J Exp Clin Cancer Res. 2018;37:95.CrossRef Marchesi F, Regazzo G, Palombi F, Terrenato I, Sacconi A, Spagnuolo M, et al. Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study. J Exp Clin Cancer Res. 2018;37:95.CrossRef
22.
go back to reference Pospisilova S, Pazourkova E, Horinek A, Brisuda A, Svobodova I, Soukup V, et al. MicroRNAs in urine supernatant as potential non-invasive markers for bladder cancer detection. Neoplasma. 2016;63(5):799–808.CrossRef Pospisilova S, Pazourkova E, Horinek A, Brisuda A, Svobodova I, Soukup V, et al. MicroRNAs in urine supernatant as potential non-invasive markers for bladder cancer detection. Neoplasma. 2016;63(5):799–808.CrossRef
23.
go back to reference Snowdon J, Boag S, Feilotter H, Izard J, Siemens DR. A pilot study of urinary microRNA as a biomarker for urothelial cancer. Can Urol Assoc J. 2013;7(1–2):28–32.CrossRef Snowdon J, Boag S, Feilotter H, Izard J, Siemens DR. A pilot study of urinary microRNA as a biomarker for urothelial cancer. Can Urol Assoc J. 2013;7(1–2):28–32.CrossRef
24.
go back to reference Turchinovich A, Weiz L, Burwinkel B. Extracellular miRNAs: the mystery of their origin and function. Trends Biochem Sci. 2012;37(11):460–5.CrossRef Turchinovich A, Weiz L, Burwinkel B. Extracellular miRNAs: the mystery of their origin and function. Trends Biochem Sci. 2012;37(11):460–5.CrossRef
25.
go back to reference Healy NA, Heneghan HM, Miller N, Osborne CK, Schiff R, Kerin MJ. Systemic mirnas as potential biomarkers for malignancy. Int J Cancer. 2012;131(10):2215–22.CrossRef Healy NA, Heneghan HM, Miller N, Osborne CK, Schiff R, Kerin MJ. Systemic mirnas as potential biomarkers for malignancy. Int J Cancer. 2012;131(10):2215–22.CrossRef
26.
go back to reference Tanaka M, Oikawa K, Takanashi M, Kudo M, Ohyashiki J, Ohyashiki K, et al. Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS One. 2009;4:e5532.CrossRef Tanaka M, Oikawa K, Takanashi M, Kudo M, Ohyashiki J, Ohyashiki K, et al. Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS One. 2009;4:e5532.CrossRef
27.
go back to reference Ohshima K, Inoue K, Fujiwara A, Hatakeyama K, Kanto K, Watanabe Y, et al. Let-7 microRNA family is selectively secreted into the extracellular environment via exosomes in a metastatic gastric cancer cell line. PLoS One. 2010;5(10):e13247.CrossRef Ohshima K, Inoue K, Fujiwara A, Hatakeyama K, Kanto K, Watanabe Y, et al. Let-7 microRNA family is selectively secreted into the extracellular environment via exosomes in a metastatic gastric cancer cell line. PLoS One. 2010;5(10):e13247.CrossRef
28.
go back to reference Gao JM, Huang LZ, Huang ZG, He RQ. Clinical value and potential pathways of miR-183-5p in bladder cancer: a study based on miRNA-seq data and bioinformatics analysis. Oncol Lett. 2018;15(4):5056–70.PubMedPubMedCentral Gao JM, Huang LZ, Huang ZG, He RQ. Clinical value and potential pathways of miR-183-5p in bladder cancer: a study based on miRNA-seq data and bioinformatics analysis. Oncol Lett. 2018;15(4):5056–70.PubMedPubMedCentral
29.
go back to reference Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466–5.CrossRef Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466–5.CrossRef
30.
go back to reference May M, Burger M, Brookman-May S, Stief CG, Fritsche HM, Roigas J, et al. EORTC progression score identifies patients at high risk of cancer-specific mortality after radical cystectomy for secondary muscle-invasive bladder cancer. Clin Genitourin Cancer. 2014;12(4):278–86.CrossRef May M, Burger M, Brookman-May S, Stief CG, Fritsche HM, Roigas J, et al. EORTC progression score identifies patients at high risk of cancer-specific mortality after radical cystectomy for secondary muscle-invasive bladder cancer. Clin Genitourin Cancer. 2014;12(4):278–86.CrossRef
Metadata
Title
Urinary expression of let-7c cluster as non-invasive tool to assess the risk of disease progression in patients with high grade non-muscle invasive bladder Cancer: a pilot study
Authors
Manuela Spagnuolo
Manuela Costantini
Mariaconsiglia Ferriero
Marco Varmi
Isabella Sperduti
Giulia Regazzo
Lucia Cicchillitti
Ana Belén Díaz Méndez
Giovanni Cigliana
Vincenzo Pompeo
Andrea Russo
Valentina Laquintana
Riccardo Mastroianni
Giulia Piaggio
Umberto Anceschi
Aldo Brassetti
Alfredo Bove
Gabriele Tuderti
Rocco Simone Flammia
Michele Gallucci
Giuseppe Simone
Maria Giulia Rizzo
Publication date
01-12-2020
Publisher
BioMed Central
Keyword
Biomarkers
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2020
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-020-01550-w

Other articles of this Issue 1/2020

Journal of Experimental & Clinical Cancer Research 1/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine